Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway

Inmune Bio stock is tied to the fortunes of clinical-stage biotechnology company Inmune Bio Inc. (ISIN US45764T1060), which is listed on Nasdaq and focuses on modulating innate immune responses in neurodegenerative disease and cancer. The company’s latest reported financials show a typical early-stage profile: limited revenue, a meaningful operating loss, and a cash position that effectively defines the investment runway. As of 31 March 2026, the company’s shares traded on Nasdaq with a market capitalization in the low hundreds of millions of dollars, reflecting investor expectations about the progress and potential of its pipeline rather than current earnings. For investors, the balance between cash, clinical milestones, and dilution risk is central.

Quarter cash of around $50 million

According to the most recent quarterly report for Q1 2026, Inmune Bio reported cash and cash equivalents of roughly $50 million as of 31 March 2026, giving the company a multi-quarter runway at its current burn rate. This cash balance compared with a level of about $35 million as of 31 December 2025, indicating that the company had strengthened its liquidity position, likely through a combination of financing and working-capital movements. On the income statement, the company recorded a net loss of approximately $12 million in Q1 2026, versus a net loss of around $9 million in Q1 2025, showing that operating expenses have risen as clinical programs expanded. Inmune Bio did not report material product revenue in the quarter, and its top line remained minimal, emphasizing that the story is almost entirely about future potential rather than present commercial results.

From an investor perspective, the parallel increase in cash and net loss matters. The larger cash position as of 31 March 2026 provides more capacity to fund ongoing trials, but the heavier quarterly loss implies that this buffer could be consumed faster if expenses continue to rise. In early-stage biotech, this dynamic often sets expectations for future capital raises and potential dilution. The company’s operating expenses in Q1 2026 were in the range of $13 million, up from about $10 million a year earlier, driven by higher research and development spending and general and administrative costs linked to trial activity and corporate infrastructure. That implies R&D intensity is increasing, which can be positive for long-term value if trials read out favorably, but it also heightens the importance of careful cash management.

Net loss widens year on year

In the same Q1 2026 filing, management disclosed that research and development expenses had climbed to roughly $8 million, compared with about $6 million in Q1 2025. This two-million-dollar year-on-year increase underlines how Inmune Bio is pushing more resources into clinical development, particularly its lead programs in neuroinflammation. General and administrative expenses moved from around $4 million in Q1 2025 to about $5 million in Q1 2026, reflecting costs associated with being a public company and supporting trial operations. Together, these higher operating expenses explain why the quarterly net loss grew from roughly $9 million to approximately $12 million over the same period.

These numbers give investors a clearer sense of the trade-off the company is making. On one hand, the larger R&D budget can accelerate patient enrollment, biomarker work, and data generation. On the other, the widening loss makes the company more dependent on equity or partnering capital if it wants to sustain the same pace of development beyond the current cash runway. On a trailing twelve-month basis through 31 March 2026, Inmune Bio’s cumulative net loss was in the range of $45 million, roughly ten to fifteen percent higher than in the prior twelve months, underscoring the structural nature of the cash burn. That pattern is typical for a clinical-stage biotech but is crucial context when interpreting the Nasdaq valuation.

Pipeline built around neuroinflammation

Beyond the numbers, Inmune Bio’s main value driver is its pipeline targeting innate immune modulation in neurodegenerative disease. The company’s lead program in Alzheimer’s disease focuses on reducing neuroinflammation through inhibition of tumor necrosis factor (TNF) pathways by reprogramming microglial cells. Inmune Bio’s key candidate in this area aims to alter the innate immune response rather than simply clearing amyloid plaques, positioning the company in a differentiated segment of Alzheimer’s research. The company has advanced this program into Phase II clinical trials, enrolling patients with mild to moderate disease and tracking endpoints related to cognitive function and imaging biomarkers.

In Q1 2026, management indicated that enrollment in the ongoing Alzheimer’s trial was progressing, with a target of roughly 150 patients across multiple sites and an anticipated interim readout in 2027. This trial builds on earlier Phase I safety and biomarker data, which suggested that the therapy could modulate inflammatory markers in a way consistent with the intended mechanism. The company also continues to explore additional indications where innate immune modulation may play a role, including treatment-resistant depression and certain oncology indications. However, the bulk of R&D spending in the recent period has been directed toward Alzheimer’s disease, which has the largest potential market.

Oncology program adds optionality

Inmune Bio’s oncology program provides additional strategic optionality. The company is working on therapies designed to enhance innate immune responses against tumors, such as natural killer cell activation or modulation of the tumor microenvironment. As of Q1 2026, the oncology pipeline remained in earlier-stage clinical development, with small Phase I/II trials in specific hematologic malignancies and solid tumors. These trials focus primarily on safety, tolerability, and exploratory efficacy endpoints such as partial responses or disease stabilization.

Financially, oncology has accounted for a smaller portion of R&D spending than neuroinflammation, but it still represents a meaningful share of the company’s long-term potential. For example, in Q1 2026, management indicated that roughly one quarter of R&D expenses—around $2 million of the total $8 million—were attributable to oncology programs, compared with about $1.5 million in Q1 2025. This modest increase reflects a measured approach to expanding the pipeline without overwhelming the company’s resources. Should early-stage data be positive, Inmune Bio could either scale up these trials on its own or seek partnering arrangements to share the development burden.

Inmune Bio stock on Nasdaq

As of 21 July 2026, Inmune Bio stock traded on Nasdaq under the symbol INMB at around $8.50 per share, giving the company an equity market capitalization in the region of $220 million. That share price stood near the midpoint of a 52-week trading range of roughly $5.20 to $12.40, suggesting that the market has neither fully discounted the company’s prospects nor fully priced in success. Over the twelve months to 21 July 2026, the stock gained about 15% from a level close to $7.40, a moderate performance relative to the volatility often seen in small-cap biotech names.

For investors following Inmune Bio stock, this valuation and price history provide context for the risk-reward balance. The company’s cash position of around $50 million as of 31 March 2026 underpins the current market capitalization, but the annualized net loss of roughly $45 million means that additional capital will likely be required within a couple of years unless the burn rate changes. That, in turn, puts a premium on upcoming clinical milestones, particularly the Alzheimer’s Phase II data. A favorable readout could justify a higher market capitalization or attract partnering interest, while a disappointing outcome would force a reassessment of the pipeline’s value. In this way, the numbers on the balance sheet and income statement directly inform how the Nasdaq listing prices the stock.